J&J Slid 6% on a Beat — The Two-Speed Split Inside Its $25.4B Quarter

Johnson & Johnson beat revenue by roughly $0.12B and adjusted EPS by $0.06 — modest top-line beats that hide a sharp split. Innovative Medicine grew 7.9% operationally, more than three times MedTech's 2.5%, while US sales of $14.96B carried international at $10.44B (+1.6% operationally). Adjusted EPS at $2.59 is down 7.5% year-over-year against Q3 2025's $2.80, and the FY26 raise — from a prior guide midpoint to $11.10 — confirms 2026 is a transition year, not a re-acceleration.

Within Innovative Medicine, biosimilar erosion of Stelara accelerated to a 54.4% reported-operational decline — sales of $716M in Q3 FY2026 against a high in the prior-year quarter. Tremfya more than offset the loss, jumping 68.3% reported to $2.4B on psoriatic-arthritis and IBD uptake, while Darzalex grew 16.4% to $4.24B. Innovative Medicine as a whole expanded 7.9% operationally, but the franchise's headline growth looks healthier than its underlying product trajectory.

MedTech posted $8.64B in sales, up just 2.5% operationally against the $8.71B Street estimate — the second consecutive miss for the unit. Inside the segment, Vision grew 4.4% to $1.46B and Orthopedics added 3.2% to $2.35B, while Abiomed — the heart-pump business acquired in 2022 — declined 1.5% operationally to $412M on lower patient volumes. Electrophysiology grew 4.4%. Management flagged China value-based-procurement pricing and Middle East geopolitical disruption as macro drivers, with company-specific weakness in US Cardiovascular and ex-US Surgery the most actionable exposure.

Johnson & Johnson had been trading at a market cap north of $600B, with shares priced in part on a diversification narrative. The Q3 reveal — Innovative Medicine carrying the entire consolidated growth number while MedTech laps an active headwind list — broke that narrative. The 6% slide is the multiple compression implied by that gap.

Three catalysts frame the next two quarters. First, US approval of VARIPULSE Pro — Johnson & Johnson's next-generation pulsed-field ablation system for atrial fibrillation — is expected in Q4, having already cleared Japan; the platform has treated more than 100,000 AFib patients worldwide. Second, the OTTAVA general-surgery robotics system is in limited market release, representing the company's direct answer to Intuitive Surgical's da Vinci franchise. Third, the talc-litigation settlement is conditioned on 95% claimant participation — J&J says it is 'trending to meet' that threshold, and confirming it would remove a multi-quarter legal reservation against the stock.

The Q4 trade is whether MedTech re-acceleration — driven by VARIPULSE, OTTAVA and incremental share in Cardiovascular — can outrun late-cycle Darzalex deceleration and post-2026 immunology comparables. The analyst-aggregator price target near $280 sits well above the post-print share price, leaving a gap that Q4 pipeline news either closes or widens. With MedTech's organic growth mathematically capped at high-single-digits until China VBP annualizes, that gap is the bull-bear spread the market has yet to resolve.